Is Cdc25 a Druggable Target?

Author(s): John S. Lazo, Peter Wipf

Journal Name: Anti-Cancer Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)

Volume 8 , Issue 8 , 2008

Become EABM
Become Reviewer
Call for Editor


Proper control of cell cycle progression requires the functionality of a small family of activating phosphatases termed Cdc25, which have been implicated in cancer and Alzheimers disease. These protein tyrosine phosphatases are therefore recognized as attractive molecular targets for small molecules. We review the rationale, approaches, progress and challenges for developing small molecule inhibitors of the Cdc25 family. A number of potential chemical probes are discussed and their characteristics are summarized.

Keywords: Protein tyrosine phosphatase, natural products, enzyme assays, reactive oxygen species

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2008
Published on: 01 March, 2012
Page: [837 - 842]
Pages: 6
DOI: 10.2174/187152008786847738
Price: $65

Article Metrics

PDF: 7